Is inconsistency of α-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence?

World Journal of Gastroenterology

Volumn 16, Issue 24, 2010, Pages 3049-3055

  Hsieh, Chung Bao ^a,b   Chen, Teng Wei ^a   Chu, Chi Ming ^c   Chu, Heng Cheng ^a   Yu, Cheng Ping ^a   Chung, Kuo Piao ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Hepatocellular carcinoma; Inconsistent a fetoprotein; Outcome; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RECURRENCE RISK; TUMOR VOLUME; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77954561322     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i24.3049     Document Type: Article

References (21)

1. Chen DS, Sung JL. Serum alphafetoprotein in hepatocellular carcinoma. Cancer 1977; 40: 779-783
2. Peng SY, Lai PL, Chu JS, Lee PH, Tsung PT, Chen DS, Hsu HC. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993; 17: 35-41
3. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72 Suppl 1: 2-15
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
5. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and betacatenin mutations. Int J Cancer 2004; 112: 44-50
6. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308
7. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23: 1747-1753
8. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnà L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524-532
9. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic re- currence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229: 216-222
10. Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, Kim BR. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 618-629
11. Choi D, Lim HK, Rhim H, Kim YS, Yoo BC, Paik SW, Joh JW, Park CK. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: longterm results and prognostic factors. Ann Surg Oncol 2007; 14: 2319-2329
12. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-1181
13. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, Zhu YR. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-209
14. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000; 6: 320-325
15. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancers (Version 1, 2009). Available from: URL: http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf
16. Chen YJ, Yeh SH, Chen JT, Wu CC, Hsu MT, Tsai SF, Chen PJ, Lin CH. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 2000; 119: 431-440
17. Chen PJ, Chen DS, Lai MY, Chang MH, Huang GT, Yang PM, Sheu JC, Lee SC, Hsu HC, Sung JL. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 1989; 96: 527-529
18. Ding SF, Jalleh RP, Wood CB, Bowles L, Delhanty JD, Dooley J, Habib NA. Different DNA changes in primary and recurrent hepatocellular carcinoma. Gut 1992; 33: 1433-1435
19. Okusaka T, Okada S, Nose H, Ishii H, Nakasuka H, Nakayama H, Nagahama H, Yoshimori M, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S. The prognosis of patients with hepatocellular carcinoma of multicentric origin. Hepatogastroenterology 1996; 43: 919-925
20. Furihata T, Sawada T, Kita J, Iso Y, Kato M, Rokkaku K, Shimoda M, Kubota K. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology 2008; 55: 1705-1709
21. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997; 64: 143-146